Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE SURE bimekizumab in moderate to severe plaque psoriasis phase 3 trial

被引：0
|
作者：
Warren, Richard B. [1 ]
Augustin, Matthias [2 ]
Gottlieb, Alice B. [3 ]
Duffin, Kristina Callis [4 ]
Ciaravino, Valerie [5 ]
Cioffi, Christopher [6 ]
Peterson, Luke [6 ]
Blauvelt, Andrew [7 ]
机构：
[1] Univ Manchester, Dermatol Ctr, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[2] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Univ Utah, Dept Dermatol, Salt Lake City, UT USA
[5] UCB Pharma, Colombes, France
[6] UCB Pharma, Raleigh, NC USA
[7] Oregon Med Res Ctr, Portland, OR USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27373
引用
下载
收藏
页码：AB138 / AB138
页数：1
相关论文
共 50 条
  • [1] Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE VIVID bimekizumab in moderate to severe plaque psoriasis phase 3 trial
    Warren, Richard B.
    Langley, Richard G.
    Asahina, Akihiko
    Augustin, Matthias
    Merola, Joseph F.
    Gottlieb, Alice B.
    Ciaravino, Valerie
    Cioffi, Christopher
    Peterson, Luke
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB137 - AB137
  • [2] Bimekizumab versus secukinumab in plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) responses accompanying achievement of complete skin clearance in the phase 3b BE RADIANT trial
    Gottlieb, Alice B.
    Langley, Richard G.
    Warren, Richard B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB25 - AB25
  • [3] Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis
    Alice B. Gottlieb
    Valerie Ciaravino
    Christopher Cioffi
    Luke Peterson
    Richard B. Warren
    Dermatology and Therapy, 2020, 10 : 1255 - 1272
  • [4] Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis
    Gottlieb, Alice B.
    Ciaravino, Valerie
    Cioffi, Christopher
    Peterson, Luke
    Warren, Richard B.
    DERMATOLOGY AND THERAPY, 2020, 10 (06) : 1255 - 1272
  • [5] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial
    Strober, Bruce E.
    Pinter, Andreas
    Warren, Richard B.
    Blauvelt, Andrew
    Sebastian, Michael
    De Cuyper, Dirk
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB138 - AB138
  • [6] Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial
    Reich, Kristian
    Merola, Joseph F.
    Elewski, Boni
    Papp, Kim A.
    Puig, Luis
    Rich, Pheobe
    Cioffi, Christopher
    Cullen, Eva
    Peterson, Luke
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB70 - AB70
  • [7] Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial
    Gottlieb, Alice B.
    Warren, Richard B.
    Augustin, Matthias
    Garcia, Llenalia
    Cioffi, Christopher
    Peterson, Luke
    Pelligra, Christopher
    Ciaravino, Valerie
    ADVANCES IN THERAPY, 2021, 38 (10) : 5253 - 5269
  • [8] Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial
    Alice B. Gottlieb
    Richard B. Warren
    Matthias Augustin
    Llenalia Garcia
    Christopher Cioffi
    Luke Peterson
    Christopher Pelligra
    Valerie Ciaravino
    Advances in Therapy, 2021, 38 : 5253 - 5269
  • [9] Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials
    Warren, Richard B.
    Gottlieb, Alice B.
    Merola, Joseph F.
    Garcia, Llenalia
    Cioffi, Christopher
    Peterson, Luke
    Pelligra, Christopher
    Ciaravino, Valerie
    DERMATOLOGY AND THERAPY, 2021, 11 (05) : 1551 - 1569
  • [10] Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials
    Richard B. Warren
    Alice B. Gottlieb
    Joseph F. Merola
    Llenalia Garcia
    Christopher Cioffi
    Luke Peterson
    Christopher Pelligra
    Valerie Ciaravino
    Dermatology and Therapy, 2021, 11 : 1551 - 1569
12345